Formulation and in vivo pharmacokinetic evaluation of ethyl cellulose-coated sustained release multiple-unit system of tacrolimus
- Authors
- Shin, Taek Hwan; Ho, Myoung Jin; Kim, Sung Rae; Im, Sung Hyun; Kim, Chang Hyun; Lee, Sangkil; Kang, Myung Joo; Choi, Young Wook
- Issue Date
- Apr-2018
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- Tacrolimus; Sustained release; Ethyl cellulose; Hypromellose; Reservoir-type pellets; Pharmacokinetics
- Citation
- INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, v.109, pp 544 - 550
- Pages
- 7
- Journal Title
- INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Volume
- 109
- Start Page
- 544
- End Page
- 550
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1011
- DOI
- 10.1016/j.ijbiomac.2017.12.111
- ISSN
- 0141-8130
1879-0003
- Abstract
- A novel once-a-day sustained-release (SR) system of tacrolimus (FK506), a poorly water-soluble immunosuppressive agent, was designed employing ethyl cellulose (EC) polymer as release retardant. Drug (5 mg) was layered onto sugar spheres (518.3 mg) with hypromellose (5 mg), to transform the drug from a crystalline to an amorphous form. Subsequently, the drug-layered pellets were recoated with EC polymer (0.5-1.5 mg) using a fluid bed granulator. Drug release from the reservoir-type pellets was markedly impeded by the outer EC-based coating layer (EC 1 mg), displaying about 60% of drug release after 8 h, regardless of the acidity of the media. In an in vivo pharmacokinetic study in fasted Cynomolgus monkeys, the drug level in blood was gradually increased over 4.7 h and high drug concentration was maintained until 24 h, with an elimination half-life of 16.6 h. There were no statistical differences between the novel SR pellets and the recently marketed SR capsule (Advagrae (R), Astellas Pharma, Japan) in terms of maximum blood concentration, area under the curve, and half-life values, in both fasted and fed states. Therefore, the novel EC-coated pellets are expected to be bioequivalent to the commercial SR capsule, providing a once-daily dosing regimen in patients with allogenic rejection. (C) 2017 Elsevier B.V. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1011)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.